全文获取类型
收费全文 | 169236篇 |
免费 | 11114篇 |
国内免费 | 2720篇 |
专业分类
耳鼻咽喉 | 198篇 |
儿科学 | 5271篇 |
妇产科学 | 1273篇 |
基础医学 | 8548篇 |
口腔科学 | 413篇 |
临床医学 | 22098篇 |
内科学 | 95217篇 |
皮肤病学 | 376篇 |
神经病学 | 3932篇 |
特种医学 | 5975篇 |
外国民族医学 | 2篇 |
外科学 | 14442篇 |
综合类 | 12082篇 |
一般理论 | 11篇 |
预防医学 | 3511篇 |
眼科学 | 273篇 |
药学 | 7117篇 |
74篇 | |
中国医学 | 890篇 |
肿瘤学 | 1367篇 |
出版年
2023年 | 4331篇 |
2022年 | 6857篇 |
2021年 | 8673篇 |
2020年 | 8050篇 |
2019年 | 5210篇 |
2018年 | 5644篇 |
2017年 | 4778篇 |
2016年 | 5036篇 |
2015年 | 5909篇 |
2014年 | 13044篇 |
2013年 | 11176篇 |
2012年 | 11045篇 |
2011年 | 10213篇 |
2010年 | 9195篇 |
2009年 | 8969篇 |
2008年 | 7309篇 |
2007年 | 7945篇 |
2006年 | 6967篇 |
2005年 | 5717篇 |
2004年 | 4917篇 |
2003年 | 4259篇 |
2002年 | 3581篇 |
2001年 | 3160篇 |
2000年 | 2892篇 |
1999年 | 2193篇 |
1998年 | 1098篇 |
1997年 | 1020篇 |
1996年 | 861篇 |
1995年 | 706篇 |
1994年 | 658篇 |
1993年 | 669篇 |
1992年 | 1355篇 |
1991年 | 1179篇 |
1990年 | 1096篇 |
1989年 | 982篇 |
1988年 | 838篇 |
1987年 | 478篇 |
1986年 | 247篇 |
1985年 | 412篇 |
1984年 | 723篇 |
1983年 | 669篇 |
1982年 | 470篇 |
1981年 | 380篇 |
1980年 | 338篇 |
1979年 | 267篇 |
1978年 | 247篇 |
1977年 | 180篇 |
1975年 | 200篇 |
1974年 | 194篇 |
1973年 | 155篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Elin Rosen-Wetterholm Oscar Cavefors Björn Redfors Sven-Erik Ricksten Elmir Omerovic Christian L. Polte Jonatan Oras 《Acta anaesthesiologica Scandinavica》2023,67(6):746-754
Introduction
Left ventricular (LV) dysfunction is estimated to occur in 10%–25% of the general intensive care unit (ICU) population and is frequently seen as regional wall motion abnormalities (RWMAs). Although RWMA is mostly attributed to myocardial ischemia or infarction, some studies have suggested that nonischemic RWMA might also be prevalent. We sought to establish that RWMA can be seen in critically ill patients with normal coronary arteries and to explore reasons for RWMA in this population.Methods
In this retrospective study, data from the hospital angiography register and the ICU register were collated between 2012 and 2019. Patients were identified who underwent angiography in conjunction with their ICU stay and had RWMA on echocardiography. Patients were divided into either those with non-obstructed or those with obstructed coronary arteries. Cardiac magnetic resonance imaging (cMRI) examinations were reviewed if they had been performed on patients with non-obstructed coronaries.Results
We identified 53 patients with RWMA and non-obstructed coronary arteries and 204 patients with RWMA and obstructed coronary arteries. Patients with non-obstructed coronary arteries were more often female, younger, and had fewer cardiovascular risk factors. They less commonly had ST elevation, but more frequently had T-wave inversion or serious arrhythmias. Troponin levels were higher in patients with obstructed coronary arteries, but NT-proBNP was similar between the groups. There were no differences in risk-adjusted 90-day mortality between patients with non-obstructed versus obstructed coronary arteries (OR 1.21, [95% CI 0.56–2.64], p = .628). In those with non-obstructed coronary arteries, follow-up echocardiography was available for 38 patients, of whom 30 showed normalization of cardiac function. Of the 14 patients with non-obstructed coronary arteries on whom cMRI was performed, 7 had a tentative diagnosis of Takotsubo syndrome or myocardial stunning; 4 had a myocardial infarction (preexisting in 3 cases); 1 patient had acute myocarditis; 1 patient had post-myocarditis; and 1 patient was diagnosed with dilated cardiomyopathy.Conclusion
RWMA can be seen to occur in critically ill patients in the absence of coronary artery obstruction. Several conditions can cause regional hypokinesia, and cMRI is useful to evaluate the underlying etiology. 相似文献4.
Mediastinal teratoma rarely causes pericarditis. We report a case of a 22-year-old young female admitted to the emergency department for inspiratory chest pain and fever with severe pericardial effusion, unexepectable the cause of pericarditis was a mediastinal teratoma. 相似文献
5.
6.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(5):1288-1291
Background and aimsThe LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology.Methods and resultsForty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH.Thirty patients completed the study, Eze treatment was not able to improve the primary EP in comparison with placebo, with and odds ratio of 1.029 (0.18–6.38), p = 0.974. Treatment emergent adverse events registered during the study were not more prevalent in the treatment arm.Conclusionsezetimibe administered on top of lifestyle and dietary modification failed to improve the histology of NASH in comparison with lifestyle and dietary modification alone.Trial accession numberClinicalTrial.gov: NCT01950884. 相似文献
7.
8.
《Journal of cardiac failure》2022,28(7):1185-1201
Sacubitril/valsartan is an angiotensin receptor/neprilysin inhibitor that the Food and Drug Administration has indicated to reduce the risk of cardiovascular hospitalization and death in patients with left ventricular ejection fraction below normal and with no specified ejection-fraction cut-off. However, clinically significant patient groups were excluded or minimally represented in sacubitril/valsartan's pivotal clinical trials. Clinicians often encounter scenarios in which a sacubitril/valsartan off-label use may be beneficial, but limited resources are available to evaluate the efficacy and safety in these patients. This state-of-the-art review describes contemporary literature for sacubitril/valsartan Food and Drug Administration off-label indications to help clinicians assess its appropriateness in these selected, clinically important groups of patients: those with acute decompensated heart failure, acute coronary syndrome, peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, adult congenital heart disease, cardiomyopathy in dialysis patients, right ventricular failure, or durable left ventricular assist device. 相似文献
9.
10.
BackgroundData is controversial regarding the existence of an “obesity paradox” in patients undergoing Transcatheter Aortic Valve Replacement (TAVR). We sought to investigate the prognostic value of the body mass index (BMI) on outcomes following TAVR.MethodsThis is an observational, single-center study involving all patients who underwent TAVR from 2009 to 2019. BMI was calculated in all patients before TAVR. The cohort was subdivided into four groups: underweight (<20 kg/m2), normal weight (≥20 to <25 kg/m2), overweight (≥25 to <30 kg/m2) and obese (≥30 kg/m2). The main endpoint was all-cause 30-day and one-year mortality.ResultsA total of 412 patients (mean age 79.6 ± 7.8 years, mean STS score 5.3 ± 3.6) were included. Patients were grouped as follows: underweight (n = 35, 8.5%), normal weight (n = 121, 29.4%), overweight (n = 140, 34%) and obese (n = 116, 28.1%). Obese patients were younger, included more females and had lower STS score than the rest of the cohort whereas underweight patients were older, had higher STS score, more chronic kidney disease, more left ventricular dysfunction and more often underwent non-transfemoral TAVR. BMI predicted 30-day survival (AUC:0.692 [95%CI 0.522–0.862]; p = 0.030) with an optimal cut-off of 24.4 (sensitivity = 66.6%, specificity = 63.6%). On multivariate analysis, higher BMI trended toward lower 30-day mortality (HR = 0.87 [95%CI 0.75–1.01]; p = 0.071).Thirty-day mortality was higher in the underweight group (8.3%) in comparison with other BMI subgroups (normal weight 2.5%, overweight 1.4%, obese 0.9%; p = 0.045). However, no significant difference was found after adjustment of confounders (all p = NS). BMI did not predict one-year mortality. No significant difference in one-year survival was observed between the four BMI subgroups (log rank p = 0.925).ConclusionBMI could represent an interesting prognostic tool for short-term mortality in patients undergoing TAVR. BMI < 20 kg/m2 was associated with higher 30-day mortality. Symptoms improved similarly in obese patients compared to lower BMI patients. For 30-day survivors, no evidence of the existence of an obesity paradox was observed in this cohort. 相似文献